Hayman Capital looks towards Vimovo patent challenge

Hayman Capital Management has its eyes set on the patent of the arthritis drug Vimovo, which is currently held by Horizon Pharmaceuticals. Kyle Bass, the manager of Hayman, claims that Vimovo’s APIs are not new, and that Vimovo should not have a patent at all, since it is only a combination of a generic pain reliever and a generic acid inhibitor. Vimovo has been a significant money maker for Horizon, bringing in $163 million in sales in 2014. The company made a total of $296 million in sales, making it the company’s most profitable drug.


Read the source article at Hedge Fund and Private Equity News